Asia Pacific Liver Fibrosis Treatment Market
Tamanho do mercado em biliões de dólares
CAGR :
% 
USD
3.77 Billion
USD
9.93 Billion
2024
2032
 Período de previsão |
2025 –2032 |
 Tamanho do mercado (ano base ) | USD 3.77 Billion |
 Tamanho do mercado ( Ano de previsão) | USD 9.93 Billion |
 CAGR |
% |
| Principais participantes do mercado |
Mercado de tratamento da fibrose hepática na Ásia-Pacífico , por tipo de tratamento (medicação e cirurgia/terapia), estádios (F2, F1, F3 e F4), indicação (esteato-hepatite não alcoólica (NASH), fibrose induzida por hepatite B e C, doença hepática alcoólica (ALD), doenças hepáticas autoimunes, distúrbios genéticos e outros), género (masculino e feminino), utilizador final (hospitais, clínicas especializadas, clínicas, centros de ambulatório e de investigação e outros), canal de distribuição ( e vendas a retalho) - tendências do setor e previsão até 2032
Tamanho do mercado de tratamento da fibrose hepática na Ásia-Pacífico
- O mercado de tratamento da fibrose hepática na Ásia-Pacífico foi avaliado em 3,77 mil milhões de dólares em 2024 e prevê-se que atinja os 9,93 mil milhões de dólares até 2032
- Durante o período previsto de 2025 a 2032, o mercado deverá crescer a uma CAGR de 12,9%, impulsionado principalmente pela crescente consciencialização dos consumidores sobre as soluções naturais de saúde.
- Este crescimento é impulsionado por fatores como o aumento da prevalência de doenças hepáticas. Além disso, a acessibilidade impulsiona o aumento do consumo de álcool.
Análise do Mercado de Tratamento da Fibrose Hepática na Ásia-Pacífico
- O número crescente de doenças hepáticas cria uma maior população de doentes que necessitam de opções terapêuticas eficazes, especialmente para condições como a hepatite B e C. Fatores contribuintes, como o aumento do consumo de álcool, hábitos alimentares pouco saudáveis e um aumento das taxas de obesidade, levaram ao diagnóstico de mais pessoas com estas doenças hepáticas.
- À medida que os danos hepáticos avançam, o risco de desenvolver fibrose hepática aumenta, colocando uma carga significativa nos sistemas de saúde para oferecer opções de tratamento eficazes. Esta crescente procura impulsiona o desenvolvimento e a disponibilidade de terapias direcionadas, alimentando o crescimento do mercado à medida que os prestadores de cuidados de saúde procuram soluções inovadoras para a gestão desta condição.
- Além disso, a crescente consciencialização entre os profissionais de saúde e o público em geral levou a que mais indivíduos fossem examinados e diagnosticados em fases iniciais da doença hepática. Os avanços nas técnicas de diagnóstico, incluindo exames de imagem e de sangue não invasivos, facilitaram a identificação da fibrose hepática mais cedo na progressão da doença. Esta detecção precoce permite intervenções oportunas, estimulando a procura de tratamentos inovadores que revertam ou controlem eficazmente a fibrose hepática.
- Por exemplo, em agosto de 2023, de acordo com um artigo publicado pelo NCBI, a doença hepática é responsável por dois milhões de mortes anualmente e é responsável por 4% de todas as mortes (1 em cada 25 mortes no mundo); aproximadamente dois terços de todas as mortes relacionadas com o fígado ocorrem em homens. Esta estatística alarmante sublinha a necessidade urgente de opções de tratamento eficazes e realça o significativo fardo para a saúde pública imposto pelas doenças hepáticas, motivando ainda mais os sistemas de saúde e as empresas farmacêuticas a priorizar o desenvolvimento de terapias inovadoras que visem especificamente a fibrose hepática e as suas causas subjacentes.
- Consequentemente, as empresas farmacêuticas e os investigadores médicos são obrigados a investir no desenvolvimento de novas opções terapêuticas, impulsionando assim o mercado, à medida que os intervenientes procuram combater a crescente incidência de doenças hepáticas e as suas complicações associadas.
Âmbito do Relatório e Segmentação do Mercado de Tratamento da Fibrose Hepática na Ásia-Pacífico
|
Atributos |
Principais insights do mercado global de tratamento da fibrose hepática |
|
Segmentos abrangidos |
|
|
Países abrangidos |
|
|
Principais participantes do mercado |
|
|
Oportunidades de mercado |
|
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include import export analysis, production capacity overview, production consumption analysis, price trend analysis, climate change scenario, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework. |
Asia-Pacific Liver Fibrosis Treatment Market Trends
“Increasing Prevalence of Liver Diseases”
- The increasing prevalence of liver diseases is emerging as a significant global health concern, contributing substantially to healthcare burdens worldwide
- Factors such as excessive alcohol consumption, rising obesity rates, viral hepatitis infections, and unhealthy lifestyles are leading to a surge in conditions like fatty liver disease, cirrhosis, and liver cancer
- The growing incidence of non-alcoholic fatty liver disease (NAFLD), particularly linked to diabetes and metabolic syndrome, is also alarming. As a result, there is an increased demand for early diagnosis, effective treatment options, and public health initiatives. This trend is expected to drive innovation and growth in the liver disease treatment market
Asia-Pacific Liver Fibrosis Treatment Market Dynamics
Drivers
“Rising Consumption of Alcohol”
- Rising alcohol consumption is a significant contributor to the global liver fibrosis treatment market due to its direct correlation with the incidence of liver diseases, particularly Alcoholic Liver Disease (ALD)
- As more individuals consume alcohol regularly and in larger quantities, the risk of developing liver-related complications, including liver fibrosis and cirrhosis, increases significantly
- Chronic alcoholism leads to inflammation, fat accumulation, and, ultimately, fibrosis as the liver undergoes repeated damage and repair
- This growing prevalence of alcohol-related liver conditions creates a pressing demand for effective treatments and management strategies to help mitigate liver damage and improve patient outcomes
For instance,
- In October 2024, as per an article published by the International Journal of Mental Health Systems, the prevalence of alcohol consumption was 54.5% and 47.7% at the baseline and follow-up, respectively. Moreover, 12% of men reported to have newly started drinking. This prevalence of alcohol consumption leads to an increased incidence of liver fibrosis globally, potentially impacting market growth
- Em Junho de 2024, de acordo com o STAT, as mortes relacionadas com o álcool estão a aumentar, e os especialistas estão particularmente preocupados com o aumento entre os jovens e as mulheres. Os EUA registaram um aumento de 25,5% nas mortes relacionadas com o álcool entre 2019 e 2020 — representando 3% de todas as mortes. Além disso, os maiores aumentos nas mortes relacionadas com o álcool ocorreram entre as pessoas dos 25 aos 34 e dos 35 aos 44 anos, onde as mortes em ambos os grupos aumentaram mais de 37%.
- Além disso, a crescente aceitação social e a normalização do consumo de álcool, particularmente nos grupos demográficos mais jovens, agravam ainda mais o problema, levando a um maior número de indivíduos em risco de alterações fibróticas no fígado.
- Esta tendência promove o crescimento do mercado de tratamento da fibrose hepática e enfatiza a importância das iniciativas de saúde pública que visam a redução do consumo de álcool e a prevenção de doenças hepáticas.
Oportunidades
“Tecnologias emergentes e tratamentos avançados no tratamento da fibrose hepática”
-
Tecnologias emergentes como a terapia genética, as terapias moleculares dirigidas e os agentes biológicos estão a transformar o panorama do tratamento
-
As inovações recentes centram-se em medicamentos que visam especificamente as vias de progressão da fibrose, como os agonistas do FXR, os inibidores do TGF-β e os agentes anti-inflamatórios. Além disso, ferramentas de diagnóstico não invasivas como a elastografia estão a melhorar a deteção precoce
-
Estes avanços oferecem tratamentos mais eficazes e personalizados para condições como a NASH (esteato-hepatite não alcoólica) e a cirrose, levando a melhores resultados para os doentes.
-
Em fevereiro de 2024, um artigo publicado na Springer Nature, O artigo analisa as abordagens emergentes para diagnosticar e inibir a fibrogénese hepática. Os avanços incluem biomarcadores não invasivos, tecnologias de imagem e terapias celulares, como as células estaminais mesenquimais. Os medicamentos antifibróticos promissores, incluindo a pirfenidona e o ácido obeticólico, juntamente com as inovações na engenharia de tecidos, nanotecnologia e modelos microfluídicos, mostram potencial para tratamentos personalizados e de precisão.
-
Um artigo de setembro de 2021 do NCBI destacou que as tecnologias emergentes no tratamento da fibrose hepática se concentram em terapias avançadas que visam vias moleculares, como a ativação das células estreladas hepáticas. Inovações como a terapia genética, produtos biológicos, inibidores de pequenas moléculas e diagnósticos não invasivos melhoram a deteção e o tratamento precoces. As terapias com células estaminais e a engenharia de tecidos também prometem reverter a fibrose e melhorar a recuperação
-
Com a evolução contínua das estratégias de tratamento e das tecnologias de diagnóstico, as terapêuticas para a fibrose hepática estão a avançar rapidamente
-
Estas inovações oferecem esperança para uma melhor gestão das doenças hepáticas, garantindo que os doentes têm acesso a tratamentos mais eficazes e personalizados, com menos efeitos secundários, melhorando, em última análise, os resultados globais em saúde.
Restrições/Desafio
“ Consciência limitada sobre as doenças hepáticas”
- A limitada sensibilização sobre as doenças do fígado dificulta o diagnóstico precoce e a intervenção adequada. Muitas pessoas desconhecem os factores de risco e os sintomas associados às doenças hepáticas, atribuindo frequentemente sinais vagos de doença a outros problemas menos graves.
- Esta falta de conhecimento adia as consultas médicas até que a doença evolua para fases avançadas, como a fibrose hepática ou a cirrose, onde as opções de tratamento se tornam mais complexas e menos eficazes.
- Consequentemente, os diagnósticos tardios reduzem o potencial de resultados bem-sucedidos do tratamento e restringem o crescimento global do mercado, ao limitar a população de doentes que procura cuidados atempados.
Por exemplo,
- Em abril de 2024, Lupin afirmou que os doentes não têm conhecimento da sua condição até que a doença atinja um estágio crítico, desencadeando uma necessidade urgente de reavaliar a abordagem de sensibilização, deteção e tratamento da saúde do fígado. No entanto, um obstáculo significativo na gestão da saúde hepática reside na compreensão limitada das doenças hepáticas e dos factores de risco associados
- Em julho de 2021, de acordo com um estudo que incluiu 11.700 adultos (maiores de 18 anos) de cinco Inquéritos Nacionais de Exame de Saúde e Nutrição, quase 96% dos adultos com DHGNA nos EUA não sabiam que tinham doença hepática, especialmente entre os adultos jovens. Por conseguinte, aumentar a sensibilização e a educação sobre a saúde hepática é crucial para melhorar os resultados dos doentes e promover uma abordagem mais proativa à gestão da fibrose hepática e à expansão do mercado de tratamento.
- Em janeiro de 2021, a Springer Nature informou que, entre os 825 doentes incluídos na análise da investigação realizada no artigo científico "Falta de sensibilização para os danos hepáticos em doentes com diabetes tipo 2", 8,1% (IC 95% 5,1%-12,7%) dos doentes com esteatose sabiam que tinham uma doença hepática. Além disso, numa amostra nacionalmente representativa de adultos norte-americanos com DM2, a prevalência de fibrose hepática avançada é elevada. Menos de 20% das pessoas com fibrose avançada sabem que têm alguma doença hepática
- A sensibilização limitada prejudica os resultados potenciais do tratamento para os doentes e sufoca o crescimento do mercado ao reduzir o número de indivíduos que interagem com os serviços de saúde desde o início
- Assim, aumentar a sensibilização e a educação sobre a saúde hepática é crucial para melhorar o diagnóstico precoce, aumentar a eficácia do tratamento e, em última análise, promover um mercado mais robusto para as terapias para a fibrose hepática.
Âmbito do mercado global de tratamento da fibrose hepática
O mercado é segmentado com base no tipo de produto, tratamento, base de origem, aplicação, via de administração, modo de compra, faixa etária, género, utilizador final e canal de distribuição.
|
Segmentação |
Sub-segmentação |
|
Por tipo de tratamento |
|
|
Por etapas |
|
|
Por Indicação |
|
|
Por utilizador final |
|
|
Por canal de distribuição |
|
Análise regional do mercado de tratamento da fibrose hepática na Ásia-Pacífico
“A China é a região dominante no mercado dos mainframe”
- A China lidera o mercado de tratamento da fibrose hepática na Ásia-Pacífico, impulsionada pela sua robusta infraestrutura de saúde, elevada prevalência de doenças relacionadas com o fígado e forte foco no diagnóstico precoce e nas estratégias de intervenção.
- O país beneficia de uma ampla cobertura de saúde, de políticas de reembolso bem estabelecidas e de uma procura crescente por opções de diagnóstico e tratamento não invasivas.
- A liderança da China na investigação clínica e a sua participação ativa em campanhas de sensibilização para as doenças hepáticas apoiam ainda mais o crescimento do mercado
- A crescente adoção de terapias avançadas, a crescente consciencialização dos doentes e as iniciativas governamentais para combater as doenças hepáticas crónicas contribuem para o domínio da Alemanha na região.
“A China deverá registar a maior taxa de crescimento”
- A China é também o mercado de crescimento mais rápido, impulsionado pela inovação contínua em biomarcadores de fibrose, pelo aumento dos investimentos em I&D por parte das empresas farmacêuticas e pelo aumento das taxas de doenças hepáticas gordurosas relacionadas com o álcool e não alcoólicas.
- Estes factores posicionam colectivamente a China como um centro central para o tratamento da fibrose hepática na Ásia-Pacífico, tornando-a o maior e mais rápido mercado em expansão na região.
Participação no mercado de tratamento da fibrose hepática na região Ásia-Pacífico
O cenário competitivo do mercado fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, presença na Ásia-Pacífico, localizações e instalações de produção, capacidades de produção, pontos fortes e fracos da empresa, lançamento de produtos, amplitude e abrangência do produto, domínio da aplicação. Os pontos de dados fornecidos acima estão apenas relacionados com o foco das empresas em relação ao mercado.
Os principais líderes de mercado que operam no mercado são:
- F. Hoffmann-La Roche Ltd (Suíça)
- Abbott (EUA)
- La Renon Healthcare Pvt. Lda. (Índia)
- GENFIT SA (França)
- Madrigal Pharmaceuticals (EUA)
- Aligos Therapeutics (EUA)
- Pfizer, Lda. (EUA)
- Enanta Pharmaceuticals, Inc.
- Bristol-Myers Squibb Company (EUA)
- Vertex Pharmaceuticals Incorporated (EUA)
- Takeda Pharmaceutical Company Limited (Japão)
- Hepion Pharmaceuticals (EUA)
- Echosens (França)
- Galectin Therapeutics, Inc. (EUA)
- Conatus Pharmaceuticals (EUA)
- Tvardi Therapeutics (EUA)
- Viking Therapeutics (EUA)
- Calliditas Therapeutics AB (Suécia)
- Novomedix (EUA)
- Galecto Biotech (Dinamarca)
- Pilant Therapeutics, Inc. (EUA)
- Sagimet Biosciences (EUA)
- Gyre Therapeutics, Inc. (EUA)
- Akero Therapeutics, Inc. (EUA)
- CureVac SE (Alemanha)
- Novo Nordisk A/S (Dinamarca)
- Ipsen Pharma (França)
- AdAlta Limited (Austrália)
- Alentis Therapeutics AG (Suíça)
- Gilead Sciences, Inc. (EUA)
- AbbVie, Lda. (EUA)
- Merck & Co., Inc. (EUA)
- Novartis AG (Suíça)
- Intercept Pharmaceuticals, Inc. (EUA)
Últimos desenvolvimentos no mercado de tratamento da fibrose hepática na Ásia-Pacífico
- Em junho de 2024, a Gilead Sciences apresentou a nova investigação no Congresso da Associação Europeia para o Estudo do Fígado (EASL) de 2024, em Milão, com foco em doenças hepáticas como a colangite biliar primária (CBP), hepatite B (VHB), vírus da hepatite delta (VHD) e outras. As principais apresentações incluirão dados a longo prazo do estudo ASSURE sobre seladelpar para PBC, resultados sobre tenofovir para prevenção do cancro do fígado no VHB e conclusões dos estudos MYR204 e MYR301 sobre Hepcludex para HDV. Esta investigação destaca o compromisso da Gilead em avançar nas opções de tratamento para as doenças do fígado
- Em outubro de 2024, a Intercept Pharmaceuticals, Inc discutiu os seus esforços contínuos para explorar as diferenças e disparidades raciais no tratamento da colangite biliar primária (CBP). A empresa está a abordar como diferentes populações podem enfrentar diferentes desafios no diagnóstico, tratamento e gestão da PBC. Ao explorar estas disparidades, o Intercept visa melhorar o acesso aos cuidados e aos resultados do tratamento para todos os doentes, reduzindo potencialmente as barreiras ao tratamento eficaz das doenças hepáticas, incluindo a fibrose.
- Em novembro de 2022, a Food and Drug Administration (FDA) dos EUA aprovou o Vemlidy (tenofovir alafenamida) para o tratamento da infeção crónica pelo vírus da hepatite B (HBV) em doentes pediátricos com 12 anos ou mais com doença hepática compensada. Esta aprovação alarga a utilização do Vemlidy, que foi inicialmente aprovado em 2016 para adultos com VHB crónico. A aprovação baseia-se num ensaio clínico de Fase 2 que demonstra a eficácia e segurança do Vemlidy neste grupo de doentes mais jovens
- Em setembro de 2022, a Gilead Sciences concluiu a aquisição da MiroBio, uma empresa de biotecnologia sediada no Reino Unido focada em restaurar o equilíbrio imunitário através de agonistas que têm como alvo os recetores imunoinibitórios. A aquisição, avaliada em aproximadamente 405 milhões de dólares, fornece à Gilead a plataforma de descoberta da MiroBio e o seu portefólio de agonistas de recetores imunoinibitórios. O principal anticorpo experimental da MiroBio, o MB272, tem como alvo as células imunes para suprimir as respostas imunes inflamatórias e está atualmente em ensaios clínicos de Fase 1. Esta aquisição reforça os esforços da Gilead no tratamento de doenças crónicas imunomediadas
- Em março de 2021, a Gilead Sciences e a Novo Nordisk expandiram a sua colaboração no tratamento da esteato-hepatite não alcoólica (NASH) iniciando um ensaio clínico de Fase 2b. O estudo investiga a segurança e a eficácia do semaglutido, um agonista do recetor GLP-1 da Novo Nordisk, combinado com o cilofexor da Gilead (um agonista do FXR) e o firsocostat (um inibidor do ACC) em doentes com cirrose devido a NASH. O ensaio irá avaliar o impacto dos tratamentos na fibrose hepática e na resolução da NASH, estando o recrutamento previsto para começar no segundo semestre de 2021.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 MULTIVARIATE MODELLING
2.6 TREATMENT TYPE LIFELINE CURVE
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.8 DBMR MARKET POSITION GRID
2.9 MARKET END USER COVERAGE GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTERS FIVE FORCES ANALYSIS
4.2.1 LIVER TRANSPLANTATION VOLUME AND THEIR COST FOR LIVER FIBROSIS BY COUNTRY
4.2.2 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES FOR LIVER FIBROSIS: VOLUME AND COST BY COUNTRY
4.2.3 PARTIAL HEPATECTOMY (LIVER RESECTION) COST BY COUNTRY
4.2.4 CELL-BASED THERAPY COST FOR LIVER FIBROSIS TREATMENT BY COUNTRY
4.3 EPIDEMIOLOGY
4.3.1 INCIDENCE OF ALL BY GENDER
4.3.2 TREATMENT RATE
4.3.3 TREATMENT RATE
4.3.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
4.3.5 PATIENT TREATMENT SUCCESS RATES
4.4 MARKETED DRUG ANALYSIS
4.5 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
4.5.1 PATIENT FLOW DIAGRAM
4.5.2 KEY PRICING STRATEGIES
4.5.3 KEY PATIENT ENROLLMENT STRATEGIES
5 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF LIVER DISEASES
6.1.2 RISING CONSUMPTION OF ALCOHOL
6.1.3 RISING LIVER TRANSPLANTATION RATES
6.1.4 GROWING INCIDENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) & NASH
6.2 RESTRAINTS
6.2.1 LIMITED AWARENESS OF LIVER DISEASES
6.2.2 REGULATORY CHALLENGES
6.3 OPPORTUNITIES
6.3.1 EMERGING TECHNOLOGIES AND ADVANCED TREATMENTS IN LIVER FIBROSIS MANAGEMENT
6.3.2 PROGRESS IN PIPELINE PRODUCTS FOR LIVER FIBROSIS TREATMENT
6.3.3 STRATEGIC MERGERS AND ACQUISITIONS AMONG THE KEY PLAYERS
6.4 CHALLENGES
6.4.1 LACK OF EFFECTIVE AND APPROVED ANTI-FIBROTIC DRUGS
6.4.2 HIGH COST OF TREATMENTS IN LIVER FIBROSIS CARE
7 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE
7.1 OVERVIEW
7.2 MEDICATION
7.2.1 ANTIVIRAL AGENTS
7.2.1.1 VELPATASVIR/SOFOSBUVIR
7.2.1.2 TENOFOVIR
7.2.1.3 LEDIPASVIR/SOFOSBUVIR
7.2.1.4 SOFOSBUVIR
7.2.1.5 ENTECAVIR
7.2.2 ANTIFIBROTIC AGENTS
7.2.2.1 OBETICHOLIC ACID
7.2.2.2 TGF-Β INHIBITORS
7.2.2.3 CONNECTIVE TISSUE GROWTH FACTOR (CTGF) INHIBITORS
7.2.2.4 LYSYL OXIDASE-LIKE 2 (LOXL2) INHIBITORS
7.2.2.5 OTHERS
7.2.3 ANTI-INFLAMMATORY DRUGS
7.2.3.1 CORTICOSTEROIDS
7.2.3.1.1 PREDNISONE
7.2.3.1.2 DEXAMETHASONE
7.2.3.2 TUMOR NECROSIS FACTOR (TNF) INHIBITORS
7.2.3.2.1 INFLIXIMAB
7.2.3.2.2 ETANERCEPT
7.2.3.3 INTERLEUKIN (IL) INHIBITORS
7.2.3.3.1 IL-6 INHIBITORS (TOCILIZUMAB)
7.2.3.3.2 IL-1 INHIBITORS (ANAKINRA)
7.2.4 IMMUNOSUPPRESSANTS
7.2.4.1 MYCOPHENOLATE MOFETIL
7.2.4.2 TACROLIMUS
7.2.4.3 CYCLOSPORINE
7.2.5 MARKETED DRUGS
7.2.5.1 VELPATASVIR/SOFOSBUVIR
7.2.5.2 TENOFOVIR
7.2.5.3 LEDIPASVIR/SOFOSBUVIR
7.2.5.4 OBETICHOLIC ACID (OCA)
7.2.5.5 SOFOSBUVIR
7.2.5.6 PIRFENIDONE
7.2.5.7 OTHERS
7.2.6 PIPELINE DRUGS
7.2.7 BRANDED DRUGS
7.2.7.1 EPCLUSA
7.2.7.2 VIREAD AND VEMLIDY
7.2.7.3 OCALIVA
7.2.7.4 HARVONI
7.2.7.5 SOVALDI
7.2.7.6 BARACLUDE
7.2.7.7 ACTOS
7.2.7.8 OTHERS
7.2.8 GENERIC DRUGS
7.2.9 ORAL
7.2.10 PARENTERAL
7.2.11 OTHERS
7.3 SURGERY/THERAPY
7.3.1 LIVER TRANSPLANTATION
7.3.2 ORTHOTOPIC LIVER TRANSPLANT (OLT)
7.3.3 LIVING DONOR LIVER TRANSPLANT (LDLT)
7.3.4 SPLIT LIVER TRANSPLANTATION
7.3.5 DOMINO LIVER TRANSPLANT
7.3.6 ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES
7.3.6.1 ENDOSCOPIC VARICEAL LIGATION (EVL)
7.3.6.2 TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS)
7.3.6.3 LIVER ABLATION PROCEDURES
7.3.6.3.1 RADIOFREQUENCY ABLATION (RFA)
7.3.6.3.2 MICROWAVE ABLATION (MWA)
7.3.7 PARTIAL HEPATECTOMY (LIVER RESECTION)
7.3.7.1 SEGMENTAL RESECTION
7.3.7.2 LOBECTOMY
7.3.7.3 WEDGE RESECTION
7.3.8 CELL-BASED THERAPY
7.3.8.1 STEM CELL THERAPY
7.3.8.1.1 MESENCHYMAL STEM CELLS (MSCS)
7.3.8.1.2 HEMATOPOIETIC STEM CELLS (HSCS)
7.3.8.2 GENE THERAPY
7.3.8.2.1 CRISPR-BASED LIVER REGENERATION
7.3.8.2.2 HEPATIC STELLATE CELL (HSC) INHIBITORS
7.3.8.2.3 SIRNA-BASED THERAPIES
7.3.8.2.4 HEPATOCYTE APOPTOSIS INHIBITORS
7.3.8.2.4.1 OXIDATIVE STRESS INHIBITORS
7.3.8.2.4.2 EMRICASAN
7.3.8.2.4.3 PENTOXIFYLLINE
7.3.8.2.4.4 LOSARTAN
7.3.8.2.4.5 METHYL FERULIC ACID
7.3.8.2.4.6 OTHERS
7.4 OTHERS
8 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY STAGES
8.1 OVERVIEW
8.2 F2
8.3 F1
8.4 F3
8.5 F4
9 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY INDICATION
9.1 OVERVIEW
9.2 NON-ALCOHOLIC STEATOHEPATITIS (NASH)
9.3 HEPATITIS B & C-INDUCED FIBROSIS
9.3.1 CHRONIC HEPATITIS B VIRUS (HBV) FIBROSIS
9.3.2 CHRONIC HEPATITIS C VIRUS (HCV) FIBROSIS
9.4 ALCOHOLIC LIVER DISEASE (ALD)
9.5 AUTOIMMUNE LIVER DISEASES
9.5.1 AUTOIMMUNE HEPATITIS (AIH)
9.5.2 PRIMARY BILIARY CHOLANGITIS (PBC)
9.5.3 PRIMARY SCLEROSING CHOLANGITIS (PSC)
9.6 GENETIC DISORDERS
9.6.1 HEMOCHROMATOSIS
9.6.2 WILSON’S DISEASE
9.6.3 ALPHA-1 ANTITRYPSIN DEFICIENCY
9.7 OTHERS
10 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY GENDER
10.1 OVERVIEW
10.2 MALE
10.2.1 40-55 YEARS
10.2.2 ABOVE 55 YEARS
10.2.3 BELOW 40 YEARS
10.3 FEMALE
10.3.1 ABOVE 55 YEARS
10.3.2 40-55 YEARS
10.3.3 BELOW 40 YEARS
11 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS
11.2.1 PUBLIC HOSPITALS
11.2.2 PRIVATE HOSPITALS
11.3 SPECIALTY CLINICS
11.3.1 HEPATOLOGY CLINICS
11.3.2 GASTROENTEROLOGY CLINICS
11.4 CLINICS
11.5 AMBULATORY AND RESEARCH CENTERS
11.6 OTHERS
12 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.2.1 RETAIL SALES
12.2.1.1 HOSPITAL PHARMACY
12.2.1.2 RETAIL PHARMACY
12.2.1.3 ONLINE PHARMACY
13 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY REGION
13.1 OVERVIEW
13.2 ASIA-PACIFIC
13.2.1 CHINA
13.2.2 JAPAN
13.2.3 INDIA
13.2.4 SOUTH KOREA
13.2.5 AUSTRALIA
13.2.6 SINGAPORE
13.2.7 THAILAND
13.2.8 INDONESIA
13.2.9 MALAYSIA
13.2.10 TAIWAN
13.2.11 NEW ZEALAND
13.2.12 PHILIPPINES
13.2.13 VIETNAM
13.2.14 REST OF ASIA-PACIFIC
14 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: GLOBAL
15 SWOT ANALYSIS
16 COMPANY PROFILES
16.1 GILEAD SCIENCES, INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT/NEWS
16.2 ABBVIE, INC.
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENT
16.3 MERCK & CO, INC.
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENT
16.4 NOVARTIS AG
16.4.1 COMPANY SNAPSHOTS
16.4.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS
16.4.3 COMPANY SHARE ANALYSIS
16.4.4 PRODUCT PORTFOLIO
16.4.5 PIPELINE PRODUCT PORTFOLIO
16.4.6 RECENT DEVELOPMENT
16.5 INTERCEPT PHARMACEUTICALS, INC.
16.5.1 COMPANY SNAPSHOTS
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 REVENUE ANALYSIS AND SEGMENTED ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 PIPELINE PRODUCT PORTFOLIO
16.5.6 RECENT NEWS
16.6 ABBOTT
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 1.1.5 RECENT DEVELOPMENT
16.7 ALIGOS THERAPEUTICS
16.7.1 COMPANY SNAPSHOT
16.7.2 REVENUE ANALYSIS
16.7.3 PRODUCT PORTFOLIO
16.7.4 RECENT DEVELOPMENT
16.8 ALNICHE LIFE SCIENCES PVT. LTD.
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENT
16.9 ALENTIS THERAPEUTICS AG
16.9.1 COMPANY SNAPSHOT
16.9.2 PIPELINE PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 ADALTA LIMITED
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PIPELINE PRODUCT PORTFOLIO
16.10.4 RECENT NEWS
16.11 AKERO THERAPEUTICS, INC.
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PIPELINE PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 BRISTOL-MYERS SQUIBB
16.12.1 COMPANY SNAPSHOT
16.12.2 REVENUE ANALYSIS
16.12.3 PRODUCT PORTFOLIO
16.12.4 RECENT DEVELOPMENT
16.13 CALLIDITAS THERAPEUTICS AB
16.13.1 COMPANY SNAPSHOT
16.13.2 PIPELINE PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENT
16.14 CUREVAC SE
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENT
16.15 CONATUSPHARMA
16.15.1 COMPANY SNAPSHOT
16.15.2 PRODUCT PORTFOLIO
16.15.3 RECENT DEVELOPMENT/NEWS
16.16 ENANTA PHARMACEUTICALS, INC.
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENT
16.17 ECHOSENS
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENT/NEWS
16.18 F. HOFFMANN-LA ROCHE LTD
16.18.1 COMPANY SNAPSHOT
16.18.2 REVENUE ANALYSIS
16.18.3 COMPANY SHARE ANALYSIS
16.18.4 PRODUCT PORTFOLIO
16.18.5 RECENT DEVELOPMENT
16.19 GALECTO BIOTECH
16.19.1 COMPANY SNAPSHOT
16.19.2 REVENUE ANALYSIS
16.19.3 PIPELINE PRODUCT PORTFOLIO
16.19.4 RECENT DEVELOPMENT/NEWS
16.2 GALECTIN THERAPEUTICS, INC.
16.20.1 COMPANY SNAPSHOTS
16.20.2 REVENUE ANALYSIS AND SEGMENTAL ANALYSIS
16.20.3 PIPELINE PRODUCT PORTFOLIO
16.20.4 RECENT DEVELOPMENT
16.21 GYRE THERAPEUTICS, INC.
16.21.1 COMPANY SNAPSHOT
16.21.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS
16.21.3 PRODUCT PORTFOLIO
16.21.4 RECENT DEVELOPMENT/NEWS
16.22 GENFIT SA
16.22.1 COMPANY SNAPSHOTS
16.22.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS
16.22.3 PIPELINE PRODUCT PORTFOLIO
16.22.4 RECENT DEVELOPMENT
16.23 HEPION PHARMACEUTICALS
16.23.1 COMPANY SNAPSHOT
16.23.2 REVENUE ANALYSIS
16.23.3 PIPELINE PORTFOLIO
16.23.4 RECENT DEVELOPMENT
16.24 IPSEN PHARMA
16.24.1 COMPANY SNAPSHOT
16.24.2 REVENUE ANALYSIS
16.24.3 PIPELINE PRODUCT PORTFOLIO
16.24.4 RECENT NEWS/DEVELOPMENTS
16.25 LA RENON HEALTHCARE PVT. LTD.
16.25.1 COMPANY SNAPSHOT
16.25.2 PRODUCT PORTFOLIO
16.25.3 RECENT DEVELOPMENT
16.26 MADRIGAL PHARMACEUTICALS
16.26.1 COMPANY SNAPSHOTS
16.26.2 REVENUE ANALYSIS AND SEGMENTED ANALYSIS
16.26.3 PRODUCT PORTFOLIO
16.26.4 RECENT DEVELOPMENT
16.27 NOVO NORDISK A/S
16.27.1 COMPANY SNAPSHOT
16.27.2 REVENUE ANALYSIS
16.27.3 PIPELINE PRODUCT PORTFOLIO
16.27.4 RECENT DEVELOPMENT
16.28 NOVOMEDIX
16.28.1 COMPANY SNAPSHOT
16.28.2 PIPELINE PRODUCT PORTFOLIO
16.28.3 RECENT DEVELOPMENT
16.29 PILANT THERAPEUTICS, INC.
16.29.1 COMPANY SNAPSHOT
16.29.2 REVENUE ANALYSIS
16.29.3 PIPELINE PRODUCT PORTFOLIO
16.29.4 RECENT NEWS
16.3 PFIZER INC.
16.30.1 COMPANY SNAPSHOT
16.30.2 REVENUE ANALYSIS
16.30.3 PIPELINE PRODUCT PORTFOLIO
16.30.4 RECENT DEVELOPMENT/NEWS
16.31 SAGIMET BIOSCIENCES
16.31.1 COMPANY SNAPSHOTS
16.31.2 REVENUE ANALYSIS
16.31.3 1.1.4 PRODUCT PORTFOLIO
16.31.4 RECENT DEVELOPMENT/NEWS
16.32 TAKEDA PHARMACEUTICAL COMPANY LIMITED
16.32.1 COMPANY SNAPSHOT
16.32.2 REVENUE ANALYSIS
16.32.3 PIPELINE PRODUCT PORTFOLIO
16.32.4 PRODUCT PORTFOLIO
16.32.5 RECENT DEVELOPMENT
16.33 TVARDI THERAPEUTICS
16.33.1 COMPANY SNAPSHOT
16.33.2 PIPELINE PRODUCT PORTFOLIO
16.33.3 RECENT DEVELOPMENT/NEWS
16.34 VERTEX PHARMACEUTICALS INCORPORATED
16.34.1 COMPANY SNAPSHOT
16.34.2 REVENUE ANALYSIS
16.34.3 PRODUCT PORTFOLIO
16.34.4 RECENT DEVELOPMENT
16.35 VIKING THERAPEUTICS
16.35.1 COMPANY SNAPSHOT
16.35.2 REVENUE ANALYSIS
16.35.3 PIPELINE PRODUCT PORTFOLIO
16.35.4 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
Lista de Tabela
TABLE 1 ASIA-PACIFIC INCIDENCE OF CIRRHOSIS BY GENDER (2019)
TABLE 2 TREATMENT ADHERENCE LEVELS IN LIVER DISEASE PATIENTS
TABLE 3 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 4 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 5 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 7 ASIA-PACIFIC ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 8 ASIA-PACIFIC ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 9 ASIA-PACIFIC ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 10 ASIA-PACIFIC ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 11 ASIA-PACIFIC ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 12 ASIA-PACIFIC ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 13 ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 14 ASIA-PACIFIC CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 15 ASIA-PACIFIC CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 16 ASIA-PACIFIC CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 17 ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 18 ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 19 ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 20 ASIA-PACIFIC INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 21 ASIA-PACIFIC INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 22 ASIA-PACIFIC INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 23 ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 24 ASIA-PACIFIC IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 25 ASIA-PACIFIC IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 26 ASIA-PACIFIC IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 27 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 28 ASIA-PACIFIC MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 29 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 ASIA-PACIFIC BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 31 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 32 ASIA-PACIFIC SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 33 ASIA-PACIFIC SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 34 ASIA-PACIFIC LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 35 ASIA-PACIFIC ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 36 ASIA-PACIFIC LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 37 ASIA-PACIFIC PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 38 ASIA-PACIFIC CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 39 ASIA-PACIFIC STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 40 ASIA-PACIFIC GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 41 ASIA-PACIFIC HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 42 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 43 ASIA-PACIFIC F2 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 44 ASIA-PACIFIC F1 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 45 ASIA-PACIFIC F3 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 46 ASIA-PACIFIC F4 IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 47 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 48 ASIA-PACIFIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 49 ASIA-PACIFIC HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 50 ASIA-PACIFIC HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 ASIA-PACIFIC ALCOHOLIC LIVER DISEASE (ALD) IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 52 ASIA-PACIFIC AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 53 ASIA-PACIFIC AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 ASIA-PACIFIC GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 55 ASIA-PACIFIC GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 56 ASIA-PACIFIC OTHERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 57 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 58 ASIA-PACIFIC MALE IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 59 ASIA-PACIFIC MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 60 ASIA-PACIFIC FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 61 ASIA-PACIFIC FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 62 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 63 ASIA-PACIFIC HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 64 ASIA-PACIFIC HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 65 ASIA-PACIFIC SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 66 ASIA-PACIFIC SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 ASIA-PACIFIC CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 68 ASIA-PACIFIC AMBULATORY AND RESEARCH CENTERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 69 ASIA-PACIFIC OTHERS IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 70 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 71 ASIA-PACIFIC DIRECT TENDER IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 72 ASIA-PACIFIC RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 73 ASIA-PACIFIC RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 74 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 75 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 78 ASIA-PACIFIC ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 79 ASIA-PACIFIC ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 80 ASIA-PACIFIC ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 81 ASIA-PACIFIC ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 ASIA-PACIFIC ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 83 ASIA-PACIFIC ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 84 ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 ASIA-PACIFIC ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 86 ASIA-PACIFIC CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 87 ASIA-PACIFIC CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 88 ASIA-PACIFIC CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 89 ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 90 ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 91 ASIA-PACIFIC TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 92 ASIA-PACIFIC INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 93 ASIA-PACIFIC INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 94 ASIA-PACIFIC INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 95 ASIA-PACIFIC IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 96 ASIA-PACIFIC IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 97 ASIA-PACIFIC IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 98 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 99 ASIA-PACIFIC MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 100 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 ASIA-PACIFIC BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 102 ASIA-PACIFIC MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 103 ASIA-PACIFIC SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 104 ASIA-PACIFIC LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 105 ASIA-PACIFIC ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 106 ASIA-PACIFIC LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 107 ASIA-PACIFIC PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 108 ASIA-PACIFIC CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 109 ASIA-PACIFIC STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 110 ASIA-PACIFIC GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 111 ASIA-PACIFIC HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 113 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 114 ASIA-PACIFIC HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 115 ASIA-PACIFIC AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 116 ASIA-PACIFIC GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 117 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 118 ASIA-PACIFIC MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 119 ASIA-PACIFIC FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 120 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 121 ASIA-PACIFIC HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 122 ASIA-PACIFIC SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 123 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 124 ASIA-PACIFIC RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 125 CHINA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 126 CHINA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 127 CHINA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 128 CHINA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 CHINA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 130 CHINA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 131 CHINA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 CHINA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 133 CHINA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 134 CHINA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 135 CHINA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 136 CHINA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 137 CHINA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 138 CHINA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 139 CHINA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 140 CHINA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 141 CHINA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 142 CHINA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 CHINA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 144 CHINA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 145 CHINA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 146 CHINA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 147 CHINA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 148 CHINA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 149 CHINA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 150 CHINA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 151 CHINA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 152 CHINA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 153 CHINA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 154 CHINA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 155 CHINA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 156 CHINA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 157 CHINA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 158 CHINA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 159 CHINA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 160 CHINA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 161 CHINA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 162 CHINA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 163 CHINA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 164 CHINA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 165 CHINA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 166 CHINA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 CHINA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 168 CHINA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 CHINA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 CHINA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 171 CHINA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 172 CHINA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 173 CHINA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 174 CHINA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 JAPAN LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 176 JAPAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 177 JAPAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 178 JAPAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 179 JAPAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 180 JAPAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 181 JAPAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 182 JAPAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 183 JAPAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 184 JAPAN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 185 JAPAN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 186 JAPAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 187 JAPAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 188 JAPAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 189 JAPAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 190 JAPAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 191 JAPAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 192 JAPAN INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 193 JAPAN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 194 JAPAN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 195 JAPAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 196 JAPAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 197 JAPAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 198 JAPAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 199 JAPAN MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 200 JAPAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 JAPAN BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 202 JAPAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 203 JAPAN SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 204 JAPAN LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 205 JAPAN ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 206 JAPAN LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 207 JAPAN PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 208 JAPAN CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 209 JAPAN STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 210 JAPAN GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 211 JAPAN HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 212 JAPAN LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 213 JAPAN LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 214 JAPAN HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 215 JAPAN AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 216 JAPAN GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 217 JAPAN LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 218 JAPAN MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 219 JAPAN FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 220 JAPAN LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 221 JAPAN HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 222 JAPAN SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 JAPAN LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 224 JAPAN RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 225 INDIA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 226 INDIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 227 INDIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 228 INDIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 229 INDIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 230 INDIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 231 INDIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 INDIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 233 INDIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 234 INDIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 235 INDIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 236 INDIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 237 INDIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 238 INDIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 239 INDIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 240 INDIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 241 INDIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 242 INDIA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 243 INDIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 244 INDIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 245 INDIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 246 INDIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 247 INDIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 248 INDIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 249 INDIA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 250 INDIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 251 INDIA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 252 INDIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 253 INDIA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 254 INDIA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 255 INDIA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 256 INDIA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 257 INDIA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 258 INDIA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 INDIA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 260 INDIA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 261 INDIA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 262 INDIA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 263 INDIA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 264 INDIA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 265 INDIA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 266 INDIA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 267 INDIA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 268 INDIA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 269 INDIA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 270 INDIA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 271 INDIA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 272 INDIA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 273 INDIA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 274 INDIA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 275 SOUTH KOREA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 276 SOUTH KOREA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 277 SOUTH KOREA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 278 SOUTH KOREA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 279 SOUTH KOREA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 280 SOUTH KOREA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 281 SOUTH KOREA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 282 SOUTH KOREA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 283 SOUTH KOREA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 284 SOUTH KOREA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 285 SOUTH KOREA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 286 SOUTH KOREA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 287 SOUTH KOREA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 288 SOUTH KOREA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 289 SOUTH KOREA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 290 SOUTH KOREA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 291 SOUTH KOREA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 292 SOUTH KOREA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 293 SOUTH KOREA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 294 SOUTH KOREA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 295 SOUTH KOREA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 296 SOUTH KOREA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 297 SOUTH KOREA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 298 SOUTH KOREA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 299 SOUTH KOREA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 300 SOUTH KOREA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 301 SOUTH KOREA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 302 SOUTH KOREA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 303 SOUTH KOREA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 304 SOUTH KOREA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 305 SOUTH KOREA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 306 SOUTH KOREA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 307 SOUTH KOREA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 308 SOUTH KOREA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 309 SOUTH KOREA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 310 SOUTH KOREA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 311 SOUTH KOREA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 312 SOUTH KOREA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 313 SOUTH KOREA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 314 SOUTH KOREA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 315 SOUTH KOREA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 316 SOUTH KOREA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 317 SOUTH KOREA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 318 SOUTH KOREA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 319 SOUTH KOREA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 320 SOUTH KOREA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 321 SOUTH KOREA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 322 SOUTH KOREA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 323 SOUTH KOREA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 324 SOUTH KOREA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 325 AUSTRALIA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 326 AUSTRALIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 327 AUSTRALIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 328 AUSTRALIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 329 AUSTRALIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 330 AUSTRALIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 331 AUSTRALIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 332 AUSTRALIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 333 AUSTRALIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 334 AUSTRALIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 335 AUSTRALIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 336 AUSTRALIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 337 AUSTRALIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 338 AUSTRALIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 339 AUSTRALIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 340 AUSTRALIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 341 AUSTRALIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 342 AUSTRALIA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 343 AUSTRALIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 344 AUSTRALIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 345 AUSTRALIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 346 AUSTRALIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 347 AUSTRALIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 348 AUSTRALIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 349 AUSTRALIA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 350 AUSTRALIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 351 AUSTRALIA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 352 AUSTRALIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 353 AUSTRALIA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 354 AUSTRALIA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 355 AUSTRALIA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 356 AUSTRALIA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 357 AUSTRALIA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 358 AUSTRALIA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 359 AUSTRALIA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 360 AUSTRALIA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 361 AUSTRALIA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 362 AUSTRALIA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 363 AUSTRALIA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 364 AUSTRALIA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 365 AUSTRALIA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 366 AUSTRALIA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 367 AUSTRALIA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 368 AUSTRALIA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 369 AUSTRALIA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 370 AUSTRALIA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 371 AUSTRALIA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 372 AUSTRALIA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 373 AUSTRALIA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 374 AUSTRALIA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 375 SINGAPORE LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 376 SINGAPORE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 377 SINGAPORE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 378 SINGAPORE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 379 SINGAPORE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 380 SINGAPORE ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 381 SINGAPORE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 382 SINGAPORE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 383 SINGAPORE ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 384 SINGAPORE ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 385 SINGAPORE ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 386 SINGAPORE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 387 SINGAPORE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 388 SINGAPORE CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 389 SINGAPORE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 390 SINGAPORE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 391 SINGAPORE TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 392 SINGAPORE INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 393 SINGAPORE INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 394 SINGAPORE INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 395 SINGAPORE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 396 SINGAPORE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 397 SINGAPORE IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 398 SINGAPORE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 399 SINGAPORE MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 400 SINGAPORE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 401 SINGAPORE BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 402 SINGAPORE MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 403 SINGAPORE SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 404 SINGAPORE LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 405 SINGAPORE ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 406 SINGAPORE LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 407 SINGAPORE PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 408 SINGAPORE CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 409 SINGAPORE STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 410 SINGAPORE GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 411 SINGAPORE HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 412 SINGAPORE LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 413 SINGAPORE LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 414 SINGAPORE HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 415 SINGAPORE AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 416 SINGAPORE GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 417 SINGAPORE LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 418 SINGAPORE MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 419 SINGAPORE FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 420 SINGAPORE LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 421 SINGAPORE HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 422 SINGAPORE SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 423 SINGAPORE LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 424 SINGAPORE RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 425 THAILAND LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 426 THAILAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 427 THAILAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 428 THAILAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 429 THAILAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 430 THAILAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 431 THAILAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 432 THAILAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 433 THAILAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 434 THAILAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 435 THAILAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 436 THAILAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 437 THAILAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 438 THAILAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 439 THAILAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 440 THAILAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 441 THAILAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 442 THAILAND INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 443 THAILAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 444 THAILAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 445 THAILAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 446 THAILAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 447 THAILAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 448 THAILAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 449 THAILAND MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 450 THAILAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 451 THAILAND BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 452 THAILAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 453 THAILAND SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 454 THAILAND LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 455 THAILAND ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 456 THAILAND LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 457 THAILAND PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 458 THAILAND CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 459 THAILAND STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 460 THAILAND GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 461 THAILAND HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 462 THAILAND LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 463 THAILAND LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 464 THAILAND HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 465 THAILAND AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 466 THAILAND GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 467 THAILAND LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 468 THAILAND MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 469 THAILAND FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 470 THAILAND LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 471 THAILAND HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 472 THAILAND SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 473 THAILAND LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 474 THAILAND RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 475 INDONESIA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 476 INDONESIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 477 INDONESIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 478 INDONESIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 479 INDONESIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 480 INDONESIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 481 INDONESIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 482 INDONESIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 483 INDONESIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 484 INDONESIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 485 INDONESIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 486 INDONESIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 487 INDONESIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 488 INDONESIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 489 INDONESIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 490 INDONESIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 491 INDONESIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 492 INDONESIA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 493 INDONESIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 494 INDONESIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 495 INDONESIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 496 INDONESIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 497 INDONESIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 498 INDONESIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 499 INDONESIA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 500 INDONESIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 501 INDONESIA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 502 INDONESIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 503 INDONESIA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 504 INDONESIA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 505 INDONESIA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 506 INDONESIA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 507 INDONESIA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 508 INDONESIA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 509 INDONESIA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 510 INDONESIA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 511 INDONESIA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 512 INDONESIA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 513 INDONESIA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 514 INDONESIA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 515 INDONESIA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 516 INDONESIA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 517 INDONESIA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 518 INDONESIA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 519 INDONESIA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 520 INDONESIA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 521 INDONESIA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 522 INDONESIA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 523 INDONESIA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 524 INDONESIA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 525 MALAYSIA LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 526 MALAYSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 527 MALAYSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 528 MALAYSIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 529 MALAYSIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 530 MALAYSIA ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 531 MALAYSIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 532 MALAYSIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 533 MALAYSIA ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 534 MALAYSIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 535 MALAYSIA ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 536 MALAYSIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 537 MALAYSIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 538 MALAYSIA CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 539 MALAYSIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 540 MALAYSIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 541 MALAYSIA TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 542 MALAYSIA INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 543 MALAYSIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 544 MALAYSIA INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 545 MALAYSIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 546 MALAYSIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 547 MALAYSIA IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 548 MALAYSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 549 MALAYSIA MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 550 MALAYSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 551 MALAYSIA BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 552 MALAYSIA MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 553 MALAYSIA SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 554 MALAYSIA LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 555 MALAYSIA ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 556 MALAYSIA LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 557 MALAYSIA PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 558 MALAYSIA CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 559 MALAYSIA STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 560 MALAYSIA GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 561 MALAYSIA HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 562 MALAYSIA LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 563 MALAYSIA LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 564 MALAYSIA HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 565 MALAYSIA AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 566 MALAYSIA GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 567 MALAYSIA LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 568 MALAYSIA MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 569 MALAYSIA FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 570 MALAYSIA LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 571 MALAYSIA HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 572 MALAYSIA SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 573 MALAYSIA LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 574 MALAYSIA RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 575 TAIWAN LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 576 TAIWAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 577 TAIWAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 578 TAIWAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 579 TAIWAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 580 TAIWAN ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 581 TAIWAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 582 TAIWAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 583 TAIWAN ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 584 TAIWAN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 585 TAIWAN ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 586 TAIWAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 587 TAIWAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 588 TAIWAN CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 589 TAIWAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 590 TAIWAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 591 TAIWAN TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 592 TAIWAN INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 593 TAIWAN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 594 TAIWAN INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 595 TAIWAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 596 TAIWAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 597 TAIWAN IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 598 TAIWAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 599 TAIWAN MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 600 TAIWAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 601 TAIWAN BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 602 TAIWAN MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 603 TAIWAN SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 604 TAIWAN LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 605 TAIWAN ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 606 TAIWAN LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 607 TAIWAN PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 608 TAIWAN CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 609 TAIWAN STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 610 TAIWAN GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 611 TAIWAN HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 612 TAIWAN LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 613 TAIWAN LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 614 TAIWAN HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 615 TAIWAN AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 616 TAIWAN GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 617 TAIWAN LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 618 TAIWAN MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 619 TAIWAN FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 620 TAIWAN LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 621 TAIWAN HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 622 TAIWAN SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 623 TAIWAN LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 624 TAIWAN RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 625 NEW ZEALAND LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 626 NEW ZEALAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 627 NEW ZEALAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 628 NEW ZEALAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 629 NEW ZEALAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 630 NEW ZEALAND ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 631 NEW ZEALAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 632 NEW ZEALAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 633 NEW ZEALAND ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 634 NEW ZEALAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 635 NEW ZEALAND ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 636 NEW ZEALAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 637 NEW ZEALAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 638 NEW ZEALAND CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 639 NEW ZEALAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 640 NEW ZEALAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 641 NEW ZEALAND TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 642 NEW ZEALAND INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 643 NEW ZEALAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 644 NEW ZEALAND INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 645 NEW ZEALAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 646 NEW ZEALAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 647 NEW ZEALAND IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 648 NEW ZEALAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 649 NEW ZEALAND MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 650 NEW ZEALAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 651 NEW ZEALAND BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 652 NEW ZEALAND MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 653 NEW ZEALAND SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 654 NEW ZEALAND LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 655 NEW ZEALAND ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 656 NEW ZEALAND LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 657 NEW ZEALAND PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 658 NEW ZEALAND CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 659 NEW ZEALAND STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 660 NEW ZEALAND GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 661 NEW ZEALAND HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 662 NEW ZEALAND LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 663 NEW ZEALAND LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 664 NEW ZEALAND HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 665 NEW ZEALAND AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 666 NEW ZEALAND GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 667 NEW ZEALAND LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 668 NEW ZEALAND MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 669 NEW ZEALAND FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 670 NEW ZEALAND LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 671 NEW ZEALAND HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 672 NEW ZEALAND SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 673 NEW ZEALAND LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 674 NEW ZEALAND RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 675 PHILIPPINES LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 676 PHILIPPINES MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 677 PHILIPPINES MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 678 PHILIPPINES ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 679 PHILIPPINES ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 680 PHILIPPINES ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 681 PHILIPPINES ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 682 PHILIPPINES ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 683 PHILIPPINES ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 684 PHILIPPINES ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 685 PHILIPPINES ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 686 PHILIPPINES CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 687 PHILIPPINES CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 688 PHILIPPINES CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 689 PHILIPPINES TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 690 PHILIPPINES TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 691 PHILIPPINES TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 692 PHILIPPINES INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 693 PHILIPPINES INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 694 PHILIPPINES INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 695 PHILIPPINES IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 696 PHILIPPINES IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 697 PHILIPPINES IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 698 PHILIPPINES MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 699 PHILIPPINES MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 700 PHILIPPINES MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 701 PHILIPPINES BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 702 PHILIPPINES MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 703 PHILIPPINES SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 704 PHILIPPINES LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 705 PHILIPPINES ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 706 PHILIPPINES LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 707 PHILIPPINES PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 708 PHILIPPINES CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 709 PHILIPPINES STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 710 PHILIPPINES GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 711 PHILIPPINES HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 712 PHILIPPINES LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 713 PHILIPPINES LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 714 PHILIPPINES HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 715 PHILIPPINES AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 716 PHILIPPINES GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 717 PHILIPPINES LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 718 PHILIPPINES MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 719 PHILIPPINES FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 720 PHILIPPINES LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 721 PHILIPPINES HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 722 PHILIPPINES SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 723 PHILIPPINES LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 724 PHILIPPINES RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 725 VIETNAM LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 726 VIETNAM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 727 VIETNAM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 728 VIETNAM ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 729 VIETNAM ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 730 VIETNAM ANTIVIRAL AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 731 VIETNAM ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 732 VIETNAM ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 733 VIETNAM ANTIFIBROTIC AGENTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 734 VIETNAM ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 735 VIETNAM ANTI-INFLAMMATORY DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 736 VIETNAM CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 737 VIETNAM CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 738 VIETNAM CORTICOSTEROIDS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 739 VIETNAM TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 740 VIETNAM TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 741 VIETNAM TUMOR NECROSIS FACTOR (TNF) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 742 VIETNAM INTERLEUKIN (IL) INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 743 VIETNAM INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 744 VIETNAM INTERLEUKIN (IL) INHIBITOR IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 745 VIETNAM IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 746 VIETNAM IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (VOLUME IN THOUSAND UNITS)
TABLE 747 VIETNAM IMMUNOSUPPRESSANTS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (ASP IN USD/UNITS)
TABLE 748 VIETNAM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG STATUS, 2018-2032 (USD THOUSAND)
TABLE 749 VIETNAM MARKETED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 750 VIETNAM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 751 VIETNAM BRANDED DRUGS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 752 VIETNAM MEDICATION IN LIVER FIBROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 753 VIETNAM SURGERY/THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 754 VIETNAM LIVER TRANSPLANTATION IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 755 VIETNAM ENDOSCOPIC & MINIMALLY INVASIVE PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 756 VIETNAM LIVER ABLATION PROCEDURES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 757 VIETNAM PARTIAL HEPATECTOMY (LIVER RESECTION) IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 758 VIETNAM CELL-BASED THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 759 VIETNAM STEM CELL THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 760 VIETNAM GENE THERAPY IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 761 VIETNAM HEPATOCYTE APOPTOSIS INHIBITORS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 762 VIETNAM LIVER FIBROSIS TREATMENT MARKET, BY STAGES, 2018-2032 (USD THOUSAND)
TABLE 763 VIETNAM LIVER FIBROSIS TREATMENT MARKET, BY INDICATION, 2018-2032 (USD THOUSAND)
TABLE 764 VIETNAM HEPATITIS B & C-INDUCED FIBROSIS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 765 VIETNAM AUTOIMMUNE LIVER DISEASES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 766 VIETNAM GENETIC DISORDERS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 767 VIETNAM LIVER FIBROSIS TREATMENT MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 768 VIETNAM MALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 769 VIETNAM FEMALE IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 770 VIETNAM LIVER FIBROSIS TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 771 VIETNAM HOSPITALS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 772 VIETNAM SPECIALTY CLINICS IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 773 VIETNAM LIVER FIBROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 774 VIETNAM RETAIL SALES IN LIVER FIBROSIS TREATMENT MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 775 REST OF ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
Lista de Figura
FIGURE 1 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF LIVER DISEASES IS EXPECTED TO DRIVE THE GROWTH OF ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET FROM 2025 TO 2032
FIGURE 12 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET IN 2025-2032
FIGURE 13 TWO SEGMENTS COMPRISE THE ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET, BY TREATMENT TYPE
FIGURE 14 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: EXECUTIVE SUMMARY
FIGURE 15 STRATEGIC DECISIONS
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET
FIGURE 17 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, 2024
FIGURE 18 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, 2025-2032 (USD THOUSAND)
FIGURE 19 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2025-2032)
FIGURE 20 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY TREATMENT TYPE, LIFELINE CURVE
FIGURE 21 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY STAGES, 2024
FIGURE 22 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY STAGES, 2025-2032 (USD THOUSAND)
FIGURE 23 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY STAGES, CAGR (2025-2032)
FIGURE 24 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY STAGES, LIFELINE CURVE
FIGURE 25 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, 2024
FIGURE 26 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, 2025-2032 (USD THOUSAND)
FIGURE 27 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, CAGR (2025-2032)
FIGURE 28 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 29 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY GENDER, 2024
FIGURE 30 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY GENDER, 2025-2032 (USD THOUSAND)
FIGURE 31 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY GENDER, CAGR (2025-2032)
FIGURE 32 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 33 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY END USER, 2024
FIGURE 34 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 35 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY END USER, CAGR (2025-2032)
FIGURE 36 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 37 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2024
FIGURE 38 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2025-2032 (USD THOUSAND)
FIGURE 39 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 40 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 41 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 42 ASIA-PACIFIC LIVER FIBROSIS TREATMENT MARKET: COMPANY SHARE 2024 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
